ChroMedX!
Ich weiß, dass hier Geduld gefragt ist, allerdings ist der neue Chef nun schon seit zweieinhalb Monaten im Amt und es scheint doch alles zu stagnieren.
Naja, an der Börse zahlt sich ja meistens dann doch Geduld aus, also halten wir lieber die Füße still und gucken, was Zeit bringt. Nur ist der Blick auf den Kurs alles andere als ermutigend und leider bröckelt er sukzessive Richtung 0,20€.
Wenns weiter so runter geht kauf günstig nach oder Steig aus.
Oder wie du schon sagtest geduld 1-2 Jahre oder weniger oder mehr, wer weiss das schon .
Wäre eine super Sache kurz rein mit 4-5 Tausend Euro und schnell raus mit 20000 gewinn und das am besten jeden Monat.
- wenns scheisse läuft, läufts scheisse (oli kahn)
- Hätte hätte fahrradkette (loddar)
Haha :)
Ein Kumpel sagte mir demletzt, es gab mal ein Unternehmrn, dass iwi auch ein Gerät hatte für Bluttest.
Das war dann alles fake. Die chefin war kurz milliardärin und dann ist alles aufgefligen. Finde aber nichts im web ...
Hoffe das hier keine parallelen sind :(
(Zitat: loddar)
in diesem sinne.... Ein schönes Wochenende!
InVidx weiter beim reduzieren 500K
https://webfiles.thecse.com/investorx/CHX/...0Fl1MfA9S5tCgxMEJY7AGp27
übrigens sind es über 82,4M Shares ;-)
March 19, 2018 – ChroMedX Corp. (the “Company”) (CSE: CHX, OTC: CHXIF, Frankfurt: EIY2), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce the appointment of Raj Kailasanathan as ChroMedX Corp. Executive Vice President, Corporate Finance.
Mr. Kailasanathan joins ChroMedX as a seasoned finance executive with over 20 years experience in the private and public industry in Asia and North America. Prior to joining ChroMedX Corp., Raj was CFO at the innovative Toronto-based Medical Devices Product Development and Contract Manufacturing organization, Kangaroo Group, Where he led finance and accounting functions and was instrumental in preparing the company for sale in April 2017 to Starfish Medical.
“It is a great pleasure to welcome Raj to ChroMedX as part of our expanded executive team. He will play a crucial role in the management and strategy of financial operations as ChroMedX grows.” said Lahav Gil, CEO & Director, ChroMedX Corp. “
Prior to joining Kangaroo, Raj acted as Director of Finance and Corporate Treasurer at TSX listed company Real Matters Inc.
“I am thrilled to have the opportunity to be part of the team and to contribute to the growth and evolution of ChroMedX, said Raj Kailansanathan, EVP Corporate Finance, ChroMedX Corp. “This is an exciting time for all involved and I’d like to thank Lahav and the board of directors for this appointment.”
About Raj Kailasanathan
Mr. Kailasanathan is a seasoned finance professional with more than 24 years of progressive experience in Asia and North America. Over the last 10 years Raj has served in executive positions for several companies in the MedTech and FinTech sectors.
Prior to joining ChroMedX Corp., Raj was the CFO at Kangaroo Group where he led the finance and accounting functions for the company. His insight, relationship management and negotiating skills assisted in the growth of the company, which eventually lead to its sale in April 2017. Prior to Kangaroo Group Raj was Director of Finance and Corporate Treasurer at the TSX listed company Real Matters Inc.
Raj is committed and passionate about maximizing long-term shareholder value, entrepreneurism, innovation, growth initiatives, and maintaining a high level of integrity and transparency.
The Company also announces that it has granted an aggregate of 300,000 options to purchase common shares of the Company exercisable at today’s closing price per share and expiring on March 20, 2023, to certain directors, officers and consultants of the Company.
ChroMedX News & Disclosure
Parties interested in keeping abreast of latest news and updates can subscribe on the Home and News pages on the Company's website at www.ChroMedX.com
trommeln die wieder, ja wird ja jetzt auch Zeit, brauchen das Vol um die restlichen Warrants zu wandeln, umso höher umso mehr Cash ;-)
aber wenn das die Pump-News sein sollen, mit dem neuen Mann, na dann gute Nacht
haben die News dazu benutzt, nochmal um 300K zu 0,40 CAD als Option für die oberen zu Verfügung zu stellen ;-)
The Company also announces that it has granted an aggregate of 300,000 options to purchase common shares of the Company exercisable at today's closing price per share and expiring on March 20, 2023, to certain directors, officers and consultants of the Company.